The Dosage and Administration section has been revised to state that Mavyret is recommended for 12 weeks in liver or kidney transplant recipients.
The guidelines were developed by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America.
In this retrospective study, only a fraction of infants receiving well-child care at the study institution were screened for hepatitis C, despite being born to mothers with a known history of hepatitis C virus infection.
The Isentress (raltegravir) and Isentrress (raltegravir) HD label was recently updated to include Week 96 data from the Phase 3 trial (ONCEMRK).
Sofosbuvir protected and rescued neural cells infected by the Zika virus in cell cultures and mouse models, and blocked transmission of the virus to mouse fetuses.
The Food and Drug Administration (FDA) has approved updated labeling for several hepatitis C virus (HCV) infection treatments.
Study authors from the University of Washington, Seattle, and Veterans Affairs Puget Sound Healthcare System in Seattle sought to investigate whether HCV eradication with DAAs could lower the risk of liver cancer in patients.
The updates include a primer on HCV resistance and guidance on treating patients who have undergone kidney transplantation.
Nearly three-quarters of all HCV infections in the U.S. and HCV-associated deaths occur in individuals born between 1945-1965.
Using several databases, the researchers examined the association of HCV infection with the incidence of CKD.
Mavyret is a once-daily, ribavirin-free treatment that combines glecaprevir, an HCV NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor.
The supplemental New Drug Application (sNDA) approval was based on data from the Phase 3 open-label, ASTRAL-5 study.
Data from a retrospective cohort study presented at The Liver Meeting® 2016 has shown that hepatitis C virus (HCV)-infected patients with advanced chronic kidney disease (CKD) "remains a challenging population to treat," with <10% receiving treatment in the early direct-acting antivirals (DAA) era.
The all-oral, ribavirin-free glecaprevir/pibrentasvir regimen achieved high SVR12 rates in non-cirrhotic patients with hepatitis C virus (HCV) genotype (GT) 4, 5, and 6 infection, the phase 3 ENDURANCE-4 study concluded at The Liver Meeting® 2016.
Ledipasvir/Sofosbuvir with or without ribavirin is associated with comparable sustained virologic response (SVR) rates for African American patients and non-African Americans who have HIV/HCV co-infection, but cirrhosis was associated with significantly poorer rates.
Patient-reported outcome scores improve significantly for HIV-HCV co-infected patients undergoing sofosbuvir and velpatasvir therapy.
Patients with HCV GT1 with decompensated cirrhosis treated in the real world with ledipasvir/sofosbuvir plus ribavirin achieved high cure rates and comparable MELD improvement to patients in clinical trials.
The prevalence of chronic liver diseases has more than doubled in the past 30 years among adolescents and young adults in the United States to about 25%, according to research presented at The Liver Meeting® 2016.